Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma

Siegel, 2020, Cancer statistics, 2020, CA Cancer J. Clin., 70, 7, 10.3322/caac.21590 Golan, 2017, Short and long-term survival in metastatic pancreatic adenocarcinoma, 1993-2013, J. Clin. Oncol., 35, 10.1200/JCO.2017.35.4_suppl.232 Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, 136, E359, 10.1002/ijc.29210 Tempero, 2019, Pancreatic adenocarcinoma, Version 1.2019, J. Natl. Compr. Canc. Netw., 17, 202, 10.6004/jnccn.2019.0014 Tempero, 2019, NCCN guidelines updates: pancreatic cancer, J. Natl. Compr. Canc. Netw., 17, 603 Schwartz, 2016, RECIST 1.1-Update and clarification: from the RECIST committee, Eur. J. Cancer, 62, 10.1016/j.ejca.2016.03.081 Network., N.C.C. Pancreatic Adenocarcinoma (Version 1.2021. Availabe online: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf (accessed on February 7, 2021). Lee, 2019, Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA, Mol. Oncol., 13, 1623, 10.1002/1878-0261.12537 Krause, 2005, Tyrosine kinases as targets for cancer therapy, N. Engl. J. Med., 353, 172, 10.1056/NEJMra044389 Sharma, 2007, Epidermal growth factor receptor mutations in lung cancer, Nat Rev Cancer, 7, 169, 10.1038/nrc2088 Ettinger, 2019, NCCN guidelines insights: non-small cell lung cancer, version 1.2020, J. Natl. Compr. Canc. Netw., 17, 1464, 10.6004/jnccn.2019.0059 Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017 She, 2003, Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling, Clin. Cancer Res., 9, 4340 Bianco, 2003, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors, Oncogene, 22, 2812, 10.1038/sj.onc.1206388 Chakravarti, 2002, Insulin-like growth factor receptor I mediates resistance to anti- epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling, Cancer Res, 62, 200 Hurbin, 2002, Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines, J. Biol. Chem., 277, 49127, 10.1074/jbc.M207584200 Erjala, 2006, Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells, Clin. Cancer Res., 12, 4103, 10.1158/1078-0432.CCR-05-2404 Waddell, 2015, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169 Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 Luchini, 2020, KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities, J. Exp. Clinic. Cancer Res., 39, 227, 10.1186/s13046-020-01732-6 da Cunha Santos, 2010, Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: national Cancer Institute of Canada Clinical Trials Group Study PA.3, Cancer, 116, 5599, 10.1002/cncr.25393 Boeck, 2013, EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104, Br. J. Cancer, 108, 469, 10.1038/bjc.2012.495 2007, KRAS mutation is a predictor of poor response to EGFR tyrosine kinase inhibitors in NSCLC, Nature Clin. Practice Oncol., 4, 503, 10.1038/ncponc0893 Zhang, 2016, The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis, Oncotarget, 7, 78985, 10.18632/oncotarget.12587 Forbes, 2015, COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucl. Acids Res, 43, D805, 10.1093/nar/gku1075 2017, Integrated genomic characterization of pancreatic ductal adenocarcinoma, Cancer Cell, 32, 185, 10.1016/j.ccell.2017.07.007 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938 Porterfield, 2004, Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: results from a phase IB trial, J. Clin. Oncol., 22, 10.1200/jco.2004.22.90140.4110 Kindler, 2006, A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis, J. Clin. Oncol., 24, 10.1200/jco.2006.24.18_suppl.4040 Gomez-Martin, 2007, A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer, J. Clin. Oncol., 25, 10.1200/jco.2007.25.18_suppl.4611 Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol., 25, 1960, 10.1200/JCO.2006.07.9525 Cecchini, 2017, EGFR exon 19 deletion in pancreatic adenocarcinoma responds to erlotinib, followed by T790M-Mediated resistance, J. Natl. Compr. Canc. Netw., 15, 1085, 10.6004/jnccn.2017.0151 Patel, 2020, Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): a case report and literature review, J. Cancer Res. Ther, 16, 950, 10.4103/jcrt.JCRT_729_18 Hong, 2020, KRAS(G12C) inhibition with Sotorasib in advanced solid tumors, N. Engl. J. Med., 383, 1207, 10.1056/NEJMoa1917239 Patricelli, 2016, Selective inhibition of oncogenic KRAS output with small molecules targeting the Inactive State, Cancer Discov, 6, 316, 10.1158/2159-8290.CD-15-1105 Lito, 2016, Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism, Science, 351, 604, 10.1126/science.aad6204 Bryant, 2014, KRAS: feeding pancreatic cancer proliferation, Trends Biochem. Sci., 39, 91, 10.1016/j.tibs.2013.12.004